Alyaa Khaled Madeeh

Dr. Alyaa Khaled Madeeh

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 April 2023 in Metabolites
Verified
Journal Article
Open access
PDF file
AHahmed Ismail Hassan ismail hassan
ahmed Ismail Hassan ismail hassan
EHEsraa Hamouda
Esraa Hamouda
HHHeba Hamouda
Heba Hamouda
HKHossam Khaled
Hossam Khaled
AJAfnan W. M. Jobran
Afnan W. M. Jobran
Marta KarazniewiczMarta Karazniewicz
Marta Karazniewicz
Glioblastoma is the most common malignant primary brain tumor in adults. Thalidomide is a vascular endothelial growth factor inhibitor that demonstrates antiangiogenic activity, and may provide additive or synergistic anti-tumor effects when co-administered with other antiangiogenic medications. This study is a comprehensive review that highlights the potential benefits of using thalidomide, in combination with other medications, to treat glioblastoma and its associated inflammatory conditions. Additionally, the review examines the mechanism of action of thalidomide in different types of tumors, which may be beneficial in treating glioblastoma. To our knowledge, a similar study has not been conducted. We found that thalidomide, when used in combination with other medications, has been shown to produce better outcomes in several conditions or symptoms, such as myelodysplastic syndromes, multiple myeloma, Crohn’s disease, colorectal cancer, renal failure carcinoma, breast cancer, glioblastoma, and hepatocellular carcinoma. However, challenges may persist for newly diagnosed or previously treated patients, with moderate side effects being reported, particularly with the various mechanisms of action observed for thalidomide. Therefore, thalidomide, used alone, may not receive significant attention for use in treating glioblastoma in the future. Conducting further research by replicating current studies that show improved outcomes when thalidomide is combined with other medications, using larger sample sizes, different demographic groups and ethnicities, and implementing enhanced therapeutic protocol management, may benefit these patients. A meta-analysis of the combinations of thalidomide with other medications in treating glioblastoma is also needed to investigate its potential benefits further.

19 December 2025 in International Journal of Surgery
Verified
Journal Article
Open access
NDNada Dardery
Nada Dardery
DADina Essam Abo-Elnour
Dina Essam Abo-Elnour
SKSadil Mohammad Bani Khaled
Sadil Mohammad Bani Khaled
AMAlyaa Khaled Madeeh
Alyaa Khaled Madeeh
SAShahd Alqato
Shahd Alqato
AKAbdulrhman Khaity
Abdulrhman Khaity
Background: Intracranial hemorrhages (ICrH), including intracerebral hemorrhage (ICH) and aneurysmal subarachnoid hemorrhage (aSAH), are life-threatening conditions leading to high mortality and long-term disability. A persistent challenge in clinical practice is identifying the most advantageous timing for surgical intervention, as existing literature reveals conflicting outcomes regarding survival, neurological recovery, and complication rates. The literature remains heterogeneous despite extensive research, presenting conflicting evidence regarding survival benefits across various surgical timeframes, from ultra-early interventions (7 days). This study aimed to determine the optimal timing for surgery in intracranial bleeding by comparing outcomes across timeframes to guide evidence-based clinical decisions. Methods: A systematic search of PubMed, Scopus, Web of Science, and Cochrane Library was conducted for studies published from 2000 to 2025. Twenty-eight observational studies, including 5919 patients, were included. Data were analyzed using random-effects models in R software, with subgroup analyses based on the time windows and type of hemorrhage. Results: Surgery performed within 24 hours significantly reduced the odds of poor GOS scores (OR: 0.53, 95% CI: 0.31–0.92) and rebleeding (OR: 0.55, 95% CI: 0.37–0.80). The network meta-analysis indicated that surgery within 48 hours is the most effective timing for reducing mortality ( P -score = 0.99). However, pairwise comparisons revealed non-significant effects (OR = 0.94, 95% CI: 0.51–1.72), underscoring the necessity for etiology-specific interpretation. Early intervention (≤72 hours) was most beneficial in aSAH, whereas ultra-early surgery (<6 hours) in traumatic ICH showed higher mortality. Surgery delayed beyond 7 days resulted in worse functional recovery. Conclusions: Early surgical intervention, particularly within 24–48 hours, improves outcomes in many cases of ICH. However, optimal timing varies with hemorrhage type. The findings resolve previous discrepancies by illustrating that treatment effects are contingent upon both the timeframe and the underlying pathology. Personalized timing strategies are essential, and further high-quality randomized trials are needed to refine clinical guidelines.